Efficacy of Osimertinib in EGFR -Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors

ConclusionsIn this non-selected population, osimertinib had remarkable efficacy in NSCLC patients with LM irrespective of the presence of theEGFR-T790M –resistance mutation. Osimertinib efficacy was rapid in several patients, even some with poor performance status.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research